Oncolytics Biotech Inc (ONCY): who owns it and who trades it
As of Nov 16, 2026, ONCY insiders reported 14 purchases worth $363K in the last 12 months. The largest buyer was Bernd R. Seizinger (Director), with $188K. 1 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Oncolytics Biotech
From the latest filingsOverall: more buying than selling. Insiders and famous investors mostly bought.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Insider trades
In the last 12 months, ONCY insiders reported $363K of open-market purchases and $0 of sales.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Mar 12, 2026 | Jared Kelly | CEO | Purchase | 5,050 | $0.96 | $4.8K | Form 4 |
| Mar 11, 2026 | James T. Parsons | Director | Purchase | 10,000 | $1.03 | $10.3K | Form 4 |
| Feb 12, 2026 | Kirk Look | CFO | Purchase | 12,000 | $0.84 | $10.1K | Form 4 |
| Feb 12, 2026 | Wayne Pisano | Director | Purchase | 30,000 | $0.84 | $25.2K | Form 4 |
| Feb 12, 2026 | Thomas Charles Heineman | Chief Medical Officer | Purchase | 12,132 | $0.83 | $10.1K | Form 4 |
| Feb 12, 2026 | Deborah Margaret Brown | Director | Purchase | 25,000 | $0.85 | $21.2K | Form 4 |
| Feb 12, 2026 | Allison Hagerman | Vice president | Purchase | 10,000 | $0.83 | $8.3K | Form 4 |
| Feb 12, 2026 | Jared Kelly | CEO | Purchase | 29,500 | $0.84 | $24.8K | Form 4 |
| Feb 12, 2026 | Patricia S Andrews | Director | Purchase | 35,400 | $0.86 | $30.4K | Form 4 |
| Feb 12, 2026 | Bernd R. Seizinger | Director | Purchase | 40,000 | $0.85 | $34K | Form 4 |
| Feb 11, 2026 | Bernd R. Seizinger | Director | Purchase | 60,000 | $0.83 | $49.8K | Form 4 |
| Feb 11, 2026 | Andrew Aromando | Chief Business Officer | Purchase | 29,600 | $0.86 | $25.5K | Form 4 |
| Feb 11, 2026 | Jared Kelly | CEO | Purchase | 5,600 | $0.84 | $4.7K | Form 4 |
| Jan 16, 2026 | Bernd R. Seizinger | Director | Purchase | 100,000 | $1.04 | $104K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Bernd R. Seizinger | Director | $188K | – | Feb 12, 2026 |
| Jared Kelly | Chief Executive Officer, Director | $34.3K | – | Mar 12, 2026 |
| Patricia S Andrews | Director | $30.4K | – | Feb 12, 2026 |
| Andrew Aromando | Chief Business Officer | $25.5K | – | Feb 11, 2026 |
| Wayne Pisano | Director | $25.2K | – | Feb 12, 2026 |
| Deborah Margaret Brown | Director | $21.2K | – | Feb 12, 2026 |
| James T. Parsons | Director | $10.3K | – | Mar 11, 2026 |
| Kirk Look | Chief Financial Officer | $10.1K | – | Feb 12, 2026 |
| Thomas Charles Heineman | Chief Medical Officer | $10.1K | – | Feb 12, 2026 |
| Allison Hagerman | VP, Product Development | $8.3K | – | Feb 12, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
ONCY short interest
Moderate short interest. 6.8% of ONCY shares are sold short: about 1 share in 15. Over the last 12 reports the number of shares short went up 26%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 8.68M ONCY shares were sold short, 6.8% of the shares outstanding, down 3.8% from the report before. At the average daily volume of 875,790 shares, buying them all back would take about 9.9 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 8.68M | 6.81% | -4% | 875,790 | 9.9 |
| Oct 15, 2026 | 9.03M | 7.08% | +22% | 1.74M | 5.2 |
| Sep 30, 2026 | 7.37M | 5.78% | -15% | 1.02M | 7.2 |
| Sep 15, 2026 | 8.65M | 6.78% | +11% | 1.20M | 7.2 |
| Aug 31, 2026 | 7.80M | 6.12% | -8% | 578,965 | 13.5 |
| Aug 14, 2026 | 8.46M | 6.64% | +3% | 668,964 | 12.7 |
| Jul 31, 2026 | 8.23M | 7.08% | +4% | 1.16M | 7.1 |
| Jul 15, 2026 | 7.95M | 6.84% | +20% | 1.90M | 4.2 |
| Jun 30, 2026 | 6.61M | 5.69% | -7% | 1.13M | 5.8 |
| Jun 15, 2026 | 7.12M | 6.13% | +3% | 1.93M | 3.7 |
| May 29, 2026 | 6.90M | 5.94% | +1% | 1.16M | 6.0 |
| May 15, 2026 | 6.86M | 5.91% | -6% | 931,317 | 7.4 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Oncolytics Biotech company events
Oncolytics Biotech filed 31 reports on Form 8-K in the last 12 months, 4 of them about an important change (leadership, listing, auditor). The latest was on Nov 9, 2026.
- Nov 9, 2026AnnouncementOncolytics Biotech Inc. issued a press release announcing translational data from patients with relapsed/refractory multiple myeloma showing pelareorep's ability to engage the immune system and to combine with standard-of-care therapies, which will be presented at the 68th American Society of… Filing
- Nov 4, 2026AnnouncementOncolytics Biotech Inc. issued a press release announcing translational data from its study in squamous cell anal cancer patients, specifically pelareorep's ability to impact the immune system in HPV-driven tumors. Filing
- Oct 27, 2026AnnouncementOncolytics Biotech Inc. issued a press release announcing updated data from Cohort 4 of the GOBLET study, which is evaluating pelareorep and atezolizumab in second-line and later squamous cell anal cancer. Filing
- Oct 20, 2026AnnouncementOncolytics Biotech Inc. issued a press release announcing the details for a REO 033 trial-in-progress abstract and e-poster that will be presented at the European Society for Medical Oncology Congress 2026. Filing
- Oct 14, 2026AnnouncementOncolytics Biotech Inc. issued a press release announcing it is expecting to receive the final grant payment from the Pancreatic Cancer Action Network later this quarter as part of wind-down enrollment activities in the GOBLET clinical study. Filing
- Oct 13, 2026AnnouncementOncolytics Biotech Inc. issued a press release announcing certain updates relating to its intellectual property portfolio and ongoing efforts to extend patent protection for pelareorep as part of the Company’s long-term value creation and development strategy. Filing
- Sep 29, 2026AnnouncementOncolytics Biotech Inc. issued a press release discussing pelareorep's ability to change the tumor microenvironment from immunologically inactive to active in hepatocellular carcinoma as a result of data published in Proceedings of the National Academy of Sciences . The information set forth in… Filing
- Sep 28, 2026AnnouncementOncolytics Biotech Inc. issued a press release announcing certain updates and progress relating to the REO 033 colorectal cancer study. Filing
- Sep 10, 2026AnnouncementOncolytics Biotech Inc. issued a press release announcing results from a preclinical study evaluating pelareorep in combination with a pan-RAS inhibitor in a RAS-driven colorectal cancer model. Filing
- Aug 18, 2026AnnouncementOncolytics Biotech Inc. issued a press release announcing feedback from the U.S. Food and Drug Administration related to the planned pivotal Part B expansion of the REO 033 colorectal cancer study and other planned study design elements. Filing
- Jul 24, 2026ListingOncolytics Biotech Inc. received a letter from the Nasdaq Listing Qualifications Staff of The Nasdaq Stock Market LLC notifying the Company that its common stock, $0.001 par value per share had closed below $1.00 per share for 30 consecutive business days and, as a result, the Company was not in… Filing
- Jul 20, 2026AnnouncementOncolytics Biotech Inc. issued a press release announcing pelareorep in combination with a checkpoint inhibitor was granted Fast Track Designation from the U.S. Food and Drug Administration for the treatment of patients with inoperable, locally recurrent or metastatic squamous cell carcinoma of the… Filing
- Jul 13, 2026AnnouncementOncolytics Biotech Inc. issued a press release announcing certain updates and progress relating to the REO 033 study. Filing
- Jul 8, 2026AuditorChanges in Registrant’s Certifying Accountant. Filing
- Jun 16, 2026AnnouncementOncolytics Biotech Inc. issued a press release announcing a new patent related to the manufacturing of pelareorep and additional updates related to pelareorep's intellectual property portfolio. Filing
- Jun 2, 2026LeadershipThe Board of Directors of Oncolytics Biotech Inc. appointed John McAdory as Chief Operating Officer of the Company. Filing
- Jun 1, 2026AnnouncementOncolytics Biotech Inc. issued a press release announcing initial preclinical data for pelareorep in combination with RAS inhibitor modalities and plans for additional studies evaluating pelareorep in combination with multiple RAS-targeted agents. Filing
- May 22, 2026AnnouncementOncolytics Biotech Inc. issued a press release announcing certain data that will be presented at the American Society of Clinical Oncology Annual Meeting. Filing
- May 4, 2026AnnouncementOncolytics Biotech Inc. issued a press release announcing certain updates from the REO 022 study in metastatic colorectal cancer. Filing
- Apr 27, 2026AnnouncementOncolytics Biotech, Inc. issued a press release announcing alignment with the U.S. Food and Drug Administration on plans for a controlled randomized pivotal study in squamous cell carcinoma of the anal canal. Filing
- Apr 6, 2026AnnouncementOncolytics Biotech Inc. entered into an Open Market Sale Agreement with Jefferies LLC, pursuant to which the Company may offer and sell from time to time through or to the agent, acting as agent or principal, shares of the Company’s common stock, par value $0.001 per share, having an aggregate… Filing
- Apr 6, 2026AnnouncementOncolytics Biotech, Inc. issued a press release announcing its upcoming Type C meeting with the U.S. Food and Drug Administration to discuss plans for a single-arm pivotal study for pelareorep and a checkpoint inhibitor in squamous cell anal carcinoma. Filing
- Apr 1, 2026LeadershipIn connection with the Domestication, the board of directors of the Company adopted the Oncolytics Biotech Inc. 2026 Incentive Award Plan, which became effective on the Effective Date. Filing
- Mar 20, 2026SharesChanged the rights of its shareholders. Filing
- Mar 19, 2026AnnouncementOncolytics Biotech, Inc. issued a press release announcing two abstracts have been accepted for presentation at the American Associate for Cancer Research Annual Meeting. Filing
- Mar 2, 2026AnnouncementOncolytics Biotech, Inc. issued a press release announcing the launch of a randomized study in second-line RAS-mutant microsatellite stable metastatic colorectal cancer patients that will be known as REO 033. Filing
- Feb 24, 2026AnnouncementOncolytics Biotech, Inc. issued a press release announcing it will prioritize registrational or registration-enabling studies in colorectal and anal cancer. Filing
- Feb 4, 2026AnnouncementOncolytics Biotech, Inc. issued a press release announcing Fast Track Designation from the U.S. Food And Drug Administration for the combination of pelareorep, bevacizumab, leucovorin, fluorouracil, irinotecan (FOLFIRI) in second-line KRAS-mutant microsatellite-stable metastatic colorectal caner. Filing
- Jan 15, 2026VoteReported shareholder vote results. Filing
- Jan 15, 2026AnnouncementOncolytics Biotech, Inc. issued a press release announcing the appointment of John McAdory as Executive Vice President of Strategy and Operations and Yujun Wu as Vice President, Head of Biostatistics. Filing
- Jan 12, 2026AnnouncementOncolytics Biotech, Inc. issued a press release announcing certain updates on the status of its intellectual property portfolio and ongoing efforts to extend patent protection for pelareorep as part of the Company’s long-term value creation and development strategy. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Oncolytics Biotech financials
Famous investors that hold ONCY
1 of the 50 well-known investors we track reported holding ONCY in their latest 13F filing. The largest position is Ken Griffin's, worth $17.1K.
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Ken Griffin · Citadel Advisors | Q3 2026 | 25,517 | $17.1K | 0.0% | +29% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
Questions about Oncolytics Biotech Inc (ONCY) stock
Are ONCY insiders buying or selling?
In the last 12 months, ONCY insiders reported 14 open-market purchases worth $363K and no sales. The latest trade was on Mar 12, 2026. See every trade.
What is the short interest in ONCY?
As of Oct 30, 2026, 8.68M ONCY shares were sold short, 6.8% of the shares outstanding, down 3.8% from the report before. At the average daily volume of 875,790 shares, buying them all back would take about 9.9 trading days (days to cover). See the history.
Which famous investors hold ONCY?
1 of the 50 well-known investors we track reported ONCY in their latest 13F filing, including Ken Griffin. The largest position is worth $17.1K. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.